NCT05357573已完成4 期
An Open-Label, Multi Center, Single-Cohort, Post-Marketing Phase 4 Study to Evaluate the Efficacy, Pharmacodynamics, and Safety of the Anti-FGF23 Antibody, KRN23, in Adult Chinese Patients With Tumor-Induced Osteomalacia (TIO)
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 3
- 主要终点
- Change from Baseline in mean serum phosphorus level at the end of the dosing cycle.
研究概览
简要总结
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in adult Chinese patients with TIO
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a clinical diagnosis of TIO based on evidence of excessive FGF23 that is not amenable to cure by surgical excision of the offending tumor (documented by Investigator)
- •Male or female Chinese patients aged ≥18 years at the time of signing the informed consent form
- •Have a fasting serum phosphorus level < 2.5 mg/dL (0.81 mmol/L) at Screening
- •Have a serum iFGF23 level ≥ 100 pg/mL by Kainos assay at Screening
- •Have a TmP/GFR < 2.5 mg/dL at Screening
- •Have an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2(using CKD-EPI formula) at Screening. Subjects with an eGFR ≥ 30 but < 60 mL/min at screening will be considered eligible so long as in the opinion of the Investigator the decline in renal function is not related to nephrocalcinosis
- •Have a corrected serum calcium level < 10.8 mg/dL (2.69 mmol/L) at Screening (Corrected serum calcium = serum calcium in mg/dL + 0.8 × [4 - serum albumin in g/dL])
- •Have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study (female patients of child-bearing potential only)
- •Be willing to use an effective method of contraception while participating in the study (sexually active patients of child bearing potential) and for 12 weeks after last dose of study drug. Women of non child bearing potential are defined as permanently sterile (i.e. due to hysterectomy or bilateral oophorectomy) or postmenopausal (defined as at least 12 months postcessation of menses without an alternative medical cause). Postmenopausal status of female patients will be confirmed with a Screening serum follicle stimulating hormone (FSH) level >40 mIU/mL
- •Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, and diagnostic, medical, and surgical history data
- •Provide written informed consent after the nature of the study has been explained, and prior to any research-related procedures
- •Be willing and able to complete all aspects of the study, adhere to the study visit schedule and comply with the assessments (in the opinion of the Investigator)
排除标准
- •Use of the following drugs within 14 days prior to screening: pharmacologic vitamin D metabolites or analogs, or drugs for treating TIO including oral phosphate, aluminum hydroxide antacids, acetazolamide, or thiazide diuretics
- •Medication to suppress parathyroid hormone (PTH) (e.g., cinacalcet hydrochloride) within 60 days prior to screening
- •Blood or blood product transfusion within 60 days prior to screening
- •History of malignancy within 5 years of study entry with the exception of PMT-MCT (phosphaturic mesenchymal tumors of the mixed connective tissue type)
- •Positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibody at Screening, or prior history of positive test
- •Predisposition to infection, or history of recurrent infection or known immunodeficiency
- •Pregnant or breastfeeding at screening or intention to become pregnant during the study; for male subjects, the partner's intention to become pregnant during the study
- •Use of an investigational product (IP) or device within 4 months prior to screening, or planning to receive other IP before completing all assessments in this study.
- •Use of KRN23, or any other therapeutic mAb within 90 days before signing the informed consent form.
- •History of allergic or anaphylactic reactions to KRN23, any of the KRN23 ingredients, or any other monoclonal antibodies
- •Anyone otherwise considered unsuitable participation in the study by the investigator or subinvestigator
研究组 & 干预措施
KRN23
Experimental
KRN23 administered subcutaneously (SC) every 4 weeks for 48 weeks. The dose varies according to serum phosphorus level which include 0.3,0.6,1.0,1.4 and 2.0 mg/kg.
干预措施: KRN23 (Drug)
结局指标
主要结局
Change from Baseline in mean serum phosphorus level at the end of the dosing cycle.
时间窗: Week 20, 24, 28, 32, 36, 40, 44 and 48
次要结局
- Change from Baseline in level of tubular reabsorption of phosphate(TRP) over time(Week 0, 4, 8, 12, 16, 24, 36 and 48)
- Change in concentration of procollagen type 1 N propeptide(P1NP) over time(Week 0, 8, 16, 24 and 48)
- Change from Baseline in mean serum phosphorus level.(Week 22)
- Proportion of patients achieving serum phosphorus level above the lower limit of normal (LLN; 2.5 mg/dL [0.81 mmol/L])(Week 22)
- Proportion of patients achieving mean serum phosphorus level above the LLN (2.5 mg/dL [0.81 mmol/L]) at the end of the dose cycle as averaged across dose period(Weeks 20, 24, 28, 32, 36, 40, 44 and 48)
- Change in concentration of carboxy-terminal cross-linked telopeptide of type 1 collagen (CTx) over time(Week 0, 8, 16, 24 and 48)
- Change in concentration of osteocalcin (OC) over time(Week 0, 8, 16, 24 and 48)
- Change from Baseline in Brief Pain Inventory (BPI) score over time(Week 0, 12, 24 and 48)
- 36-item short-form health survey (SF-36) scores to examine health-related Quality of Life(Week 0, 12, 24 and 48)
- Change from Baseline in mean level of serum 1,25(OH)2D over time(Week 0, 1, 2, 12, 16, 24, 36 and 48)
- Change from Baseline in mean level of serum creatinine over time(Week 0, 4, 8, 12, 16, 24, 36 and 48)
- Change in concentration of bone-specific alkaline phosphatase (BALP) over time(Week 0, 8, 16, 24 and 48)
- Change from Baseline in six-minute walking test (6MWT) over time(Week 0, 12, 24 and 48)
- Change from Baseline in mean level of urinary phosphorus over time(Week 0, 4, 8, 12, 16, 24, 36 and 48)
- Change in concentration of alkaline phosphatase (ALP) over time(Week 0, 8, 16, 24 and 48)
- Change from Baseline in ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) over time(Week 0, 4, 8, 12, 16, 24, 36 and 48)
- Change from Baseline in Brief Fatigue Inventory (BFI) score over time(Week 0, 12, 24 and 48)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
4 期
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHX-linked Hypophosphatemia (XLH)NCT04842019Kyowa Kirin Co., Ltd.18
已完成
4 期
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHX-linked Hypophosphatemia (XLH)NCT04842032Kyowa Kirin Co., Ltd.28
已完成
1 期
A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/OsteomalaciaX-linked Hypophosphatemic Rickets/OsteomalaciaNCT02181764Kyowa Kirin Co., Ltd.15
已完成
3 期
Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)X-linked HypophosphatemiaNCT02537431Kyowa Kirin, Inc.14
已完成
3 期
A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaXLHNCT04308096Kyowa Kirin Co., Ltd.27